What Decheng Capital does

Decheng Capital is a venture capital firm founded in 2012 that invests exclusively in life sciences companies, with assets under management of $2.5 billion or more. The firm is headquartered in Menlo Park, California, with additional offices in Shanghai and New York, providing a tri-continental footprint that supports cross-border deal flow between US and Asia-Pacific biotech ecosystems. Its portfolio spans 80 or more companies across therapeutics, diagnostics, and related life-sciences adjacencies, with the firm maintaining board or board-equivalent roles at more than 50 portfolio companies.

The firm's investment activity is concentrated in private and late-stage private financings, including PIPE transactions, Series A through C rounds, and selective co-leadership of larger syndicates. Recent transactions include a $100M PIPE for Remix Therapeutics (June 2026), a $150M co-led Series B for Syneron Bio (March 2026), and a Series A+ for Vivacta Biotechnology (April 2026). The firm has realized several large exits, notably the sale of portfolio company Alpine Immune Sciences to Vertex Pharmaceuticals for $4.9B in April 2024 and the sale of Prometheus Biosciences to Merck for $10.8B in April 2023, and has supported public-market transitions including the January 2026 IPO of portfolio company Aardvark Therapeutics.

Decheng's revenue model follows the standard venture capital structure of management fees on committed or invested capital plus carried interest on realized gains. The team comprises approximately 13 investment professionals, including recent senior hires Joan Chen (Vice President, July 2025) and Michael Notaras (Vice President, July 2023), suggesting deliberate capacity buildout at the senior investment level. Customer relationships are bilateral: portfolio companies as investees and limited partners as capital providers, with portfolio diversification across 80+ companies reducing single-asset concentration risk.

Name

Decheng Capital

Legal name

Decheng Capital LLC

Website

https://www.decheng.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Decheng Capital is a life-sciences-focused venture capital firm founded in 2012 with $2.5B+ AUM, based in Menlo Park with offices in Shanghai and New York, investing across 80+ therapeutic and diagnostic portfolio companies.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Finance Services (6199)

akta.pro primary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Life sciences venture capital
• Biotech private equity
• Healthcare growth equity
• Venture capital management
• Biopharma early stage investing

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Fund Management: As a venture capital/private equity firm managing over $2.5 billion in capital, Decheng generates revenue through management fees charged on assets under management and carried interest/performance fees on successful exits from portfolio companies. Returns are driven by equity ownership stakes in early-stage life science and growth-stage healthcare companies that may exit via IPO (NASDAQ, HKSE, SHA), strategic M&A (e.g., Merck, Vertex, Eli Lilly, Roche, Illumina), or other liquidity events.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Decheng Capital is a venture capital and private equity firm that provides equity capital and active strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. The firm manages over $2.5 billion in assets and invests across biopharma, diagnostics and tools, medical devices, and services, with offices in Silicon Valley, Shanghai, and New York enabling cross-border US-China deal flow. Revenue is generated through management fees on AUM and carried interest/performance fees on successful portfolio exits via IPO, M&A, or other liquidity events.

Product overview

Decheng Capital operates as a single global life sciences investment platform rather than a multi-product suite. Founded in 2012 by Dr. Min Cui, the firm manages over $2.5 billion in assets and provides capital and strategic support to portfolio companies spanning four categories: Biopharma (e.g., Aardvark Therapeutics, CG Oncology, Mammoth Biosciences, Mirvie, Shape Therapeutics, Syneron Bio, Vivacta Biotechnology), Diagnostics and Tools (e.g., Adaptive Biotechnologies, Encodia, LevitasBio, Watchmaker Genomics, AccuraGen), Medical Device (e.g., Nalu Medical, Polares Medical, Centricity Vision, SINO Medical), and Services (e.g., USCI Medical Laboratory). The firm's offering is unified — a life sciences venture capital platform — and is delivered through offices in Silicon Valley (Menlo Park), Shanghai, and New York. Portfolio companies include notable IPOs and exits such as Adaptive Biotechnologies (NASDAQ: ADPT), 3SBio (HKSE: 1530), AK Medical (HKSE: 1789), Invitae (NASDAQ: NVTA), GRAIL (acquired by Illumina), Cue Health (NASDAQ: HLTH), Arcus Biosciences (NASDAQ: RCUS), Terns Pharmaceuticals (NASDAQ: TERN), CG Oncology (NASDAQ: CGON), and others.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-Stage Life Sciences Venture Capital Investment Equity capital and active strategic support for early-stage life science companies with revolutionary technologies, including board representation and operational involvement. Targets biopharma, diagnostics, medical devices, and tools/services platforms.
• Growth-Stage Healthcare Growth Equity Investment Growth-stage capital and strategic support to healthcare companies with strong market presence, helping them scale commercialization, expand geographically (especially into China and the US), advance clinical pipelines, and execute cross-border strategies.
• Cross-Border US-China Life Sciences Investment Platform Integrated investment platform spanning US and China life sciences markets, providing portfolio companies with cross-border strategic support including US clinical development expertise, FDA and NMPA regulatory navigation, China clinical trial site and manufacturing partner access, and global partnership facilitation.

Quantifiable outcome

• Led a $100 million oversubscribed private placement financing for Remix Therapeutics in connection with its merger with Passage Bio (announced 2026-06-24).
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• OrbiMed Advisors: Global healthcare-dedicated investment firm managing ~$17B across private equity, royalty, and public market strategies. Highly comparable to Decheng in life sciences focus and cross-border US-Asia investment activity, with a similar breadth of biopharma, medtech, and diagnostics exposure.
• Bay City Capital: Life sciences-focused venture capital firm based in San Francisco where multiple Decheng senior team members previously worked (Min Cui, Victor Tong, Dayton Misfeldt, Nick Pliam). Closely comparable investment thesis in biopharma and tools, with similar stage and check-size orientation.
• Frazier Healthcare Ventures: US-based healthcare-dedicated venture and growth firm investing across biopharma, medical devices, and healthcare services. Comparable in life sciences focus, stage breadth (seed through growth), and portfolio size; Peter Colabuono joined Decheng from Frazier.
• ARCH Venture Partners: Premier US life sciences venture firm investing across early-stage biotech, genomics, and platform technologies with deep scientific advisor networks. Comparable in modality focus (gene editing, cell therapy, diagnostics) and ability to lead large private financings.
• Atlas Venture: Boston-based early-stage life sciences venture firm building biotech companies from inception. Comparable in investing across novel modalities (RNA, cell therapy, gene therapy) and stage focus, with comparable check sizes and board-driven model.
• Qiming Venture Partners: China-based venture firm with significant healthcare and biotech investment activity, frequently co-investing with Decheng (Syneron Bio Series B, others). Comparable in cross-border US-China life sciences investing and biotech platform thesis.
• Loyal Valley Capital: China-focused investment firm with active healthcare/biotech practice; co-led Vivacta Biotechnology Series A alongside Decheng. Directly comparable as a cross-border life sciences investor with similar modality and stage preferences.
• 5Y Capital: China-based venture firm investing in technology and healthcare; Joan Chen joined Decheng from 5Y Capital. Comparable in cross-border China-US life sciences investing and stage preferences for early through growth healthcare companies.
• MPM Capital: US-based biotech-focused investment firm investing across early-stage and public equities in oncology and other life sciences. Comparable in dedicated life sciences focus, ability to lead and co-lead large financings, and portfolio depth.

Broad incumbents

• Flagship Pioneering: Larger life sciences innovation firm that originates and builds biotech platforms internally (Moderna, etc.). Comparable in life sciences focus and ability to support breakthrough therapeutic platforms, though distinct in its origination-heavy model versus Decheng's external investment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/decheng-capital-

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments126 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Decheng Capital